Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Study summary

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRMC-4630 and Sotorasib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 6, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?60 U.S. locations

Locations may change over time.

Who runs it?Revolution Medicines, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Revolution Medicines, Inc.
Interventions being studied: Drug: RMC-4630; Drug: Sotorasib

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Targeted therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Subject must be ≥18 years of age.
Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)

Reasons someone may not be able to joinExclusion criteria

Primary central nervous system (CNS) tumors
Known or suspected leptomeningeal or brain metastases or spinal cord compression
Clinically significant cardiac disease
Known impairment of GI function that would alter the absorption
Active autoimmune disease requiring systemic treatment within past 2 years
History of severe allergic reactions to any of the study intervention components
Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Florida Cancer SpecialistsFort Myers, Florida
BRCR Medical Center Inc.Plantation, Florida
Cancer Specialists of North FloridaSaint Augustine, Florida
GenHarp Clinical SolutionsEvergreen Park, Illinois
Hematology Oncology ClinicBaton Rouge, Louisiana
New England Cancer SpecialistsScarborough, Maine
American Oncology Partners of Maryland, PABethesda, Maryland
Maryland Oncology Hematology, P.A.Columbia, Maryland
Minnesota Oncology Hematology, P.A.Minneapolis, Minnesota
Nebraska Cancer SpecialistsOmaha, Nebraska
Comprehensive Cancer Centers of NevadaLas Vegas, Nevada
New Jersey Center for Cancer ResearchBrick, New Jersey

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 6, 2026. Always confirm current availability with the study team.

View original record ↗